Travere Therapeutics, Inc.

Direct answer

Travere Therapeutics, Inc. is publicly traded on NASDAQ under the ticker TVTX.

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function...

Can you invest in Travere Therapeutics, Inc.?

Yes. Travere Therapeutics, Inc. trades publicly on NASDAQ as TVTX.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Travere Therapeutics, Inc.

Detailed equity research is provided by MarketSnap.